ACRS

Aclaris Therapeutics, Inc.

$4.15

-2.12%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.

Source: Yahoo Finance
AI summary

Price & performance

1M-38.3%
3M-38.8%
YTD+13.9%
1Y+60.0%
52-week range—
Beta1.00
Full chart and returns against a benchmark

Q-Score

45/ 100

Quality against peers; 50 is the peer median.

Growth35
Risk46
Performance60
Valuation36
Profitability45
Leverage51
Sentiment49
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$7.8M-58.2%
Net income-$64.9M
Net margin-829.6%-124.1 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

ACRSIndustryP/E—89.69P/S102.8311.88EV/EBITDA—67.10P/B3.956.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate$-0.17
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate